Скачать или смотреть Why Is Regeneron Buying 23andMe? The Confusing Billion-Dollar Biotech Move। USA Prime News

Why Is Regeneron Buying 23andMe? The Confusing Billion-Dollar Biotech Move। USA Prime News
Regeneron has stunned the biotech world by acquiring 23andMe, the once-popular consumer DNA testing company. While 23andMe holds one of the largest genetic databases in the world, the move leaves many analysts questioning the strategy behind the deal. In this video, we break down what Regeneron might gain from this acquisition, the risks involved, and what it could mean for the future of genetic data, healthcare, and personalized medicine.

From data privacy concerns to drug development strategies, we explore the possible motives behind the merger—and why the industry is split on whether it’s visionary or just a head-scratcher.

📌 Stay tuned for expert insight, market implications, and what it means for you if you’ve ever used 23andMe.

🧬 Is this the future of precision medicine—or a risky business experiment?

👍 Like, comment, and subscribe for more biotech and health tech breakdowns!

#Regeneron #23andMe #BiotechNews #DNAData #HealthTech #PersonalizedMedicine #TechMergers #Genetics #PharmaNews #BiotechInvesting